Related references
Note: Only part of the references are listed.Persistency of neutralizing antibodies depends on titer and interferon-beta preparation
Harald Hegen et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
T cells become licensed in the lung to enter the central nervous system
Francesca Odoardi et al.
NATURE (2012)
Smoking: effects on multiple sclerosis susceptibility and disease progression
Dean M. Wingerchuk
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2012)
Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis
Anna Karin Hedstrom et al.
BRAIN (2011)
Influence of apolipoprotein E plasma levels and tobacco smoking on the induction of neutralising antibodies to interferon-beta
Armando Sena et al.
JOURNAL OF NEUROLOGY (2010)
Specific interaction between genotype, smoking and autoimmunity to citrullinated α-enolase in the etiology of rheumatoid arthritis
Hiba Mahdi et al.
NATURE GENETICS (2009)
Absence of MxA induction by interferon β in patients with MS reflects complete loss of bioactivity
D. Hesse et al.
NEUROLOGY (2009)
Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis
Anna K. Hedstrom et al.
NEUROLOGY (2009)
Lung Myeloid Dendritic Cells Coordinately Induce TH1 and TH17 Responses in Human Emphysema
Ming Shan et al.
SCIENCE TRANSLATIONAL MEDICINE (2009)
HLA-DRBI*0401 and HLA-DRBI*0408 are strongly associated with the development of antibodies against interferon-β therapy in multiple sclerosis
Steve Hoffmann et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2008)
Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells
D. Makrygiannakis et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta
A. Bertolotto et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2007)
Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity
A. Sominanda et al.
MULTIPLE SCLEROSIS (2007)
Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients
C. Gneiss et al.
MULTIPLE SCLEROSIS JOURNAL (2006)
Guidelines on use of anti-IFN-β antibody measurements in multiple sclerosis:: report of an EFNS Task Force on IFN-β antibodies in multiple sclerosis
PS Sorensen et al.
EUROPEAN JOURNAL OF NEUROLOGY (2005)
Eight-year immunogenicity and safety of interferon beta-1a-Avonex® treatment in patients with multiple sclerosis
RM Herndon et al.
MULTIPLE SCLEROSIS (2005)
Immunogenicity of interferon beta: differences among products
A Bertolotto et al.
JOURNAL OF NEUROLOGY (2004)
Post-translational modifications of proteins: implications for aging, antigen recognition, and autoimmunity
PAC Cloos et al.
BIOGERONTOLOGY (2004)
Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis
PS Sorensen et al.
LANCET (2003)
Posttranslational protein modifications: new flavors in the menu of autoantigens
HA Doyle et al.
CURRENT OPINION IN RHEUMATOLOGY (2002)
Share Paper
